<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04485156</url>
  </required_header>
  <id_info>
    <org_study_id>Hi-DoRi-3</org_study_id>
    <nct_id>NCT04485156</nct_id>
  </id_info>
  <brief_title>Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)</brief_title>
  <acronym>Hi-DoRi-3</acronym>
  <official_title>Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin to 3 Months After Culture Conversion (Hi-DoRi-3): A Phase 3, Multicenter, Randomized, Open-label, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Medical Center, Seoul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Institute of Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Tuberculosis Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korean Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effectiveness and safety of the regimen
      including high dose rifampicin for individualized duration (3 months after Culture
      Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of unfavorable treatment outcomes between two arms</measure>
    <time_frame>Within 18 months of randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to unfavorable treatment outcomes</measure>
    <time_frame>Within 18 months of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to culture conversion on liquid media</measure>
    <time_frame>Censored at 2 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment success</measure>
    <time_frame>At the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with relapse of same strain</measure>
    <time_frame>At the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse with same strain</measure>
    <time_frame>through study completion, 18months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of AEs grade 3 and above</measure>
    <time_frame>through study completion, 18months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">926</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm 1 (Conventional treatment group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will be treated as recommended by Korean Guidelines For Tuberculosis as well as WHO guidelines (e.g. isoniazid, rifampicin, ethambutol, and pyrazinamide for 2 months followed by isoniazid, rifampicin, (and ethambutol)) Duration of the treatment
- 6 months in total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (High-dose rifampicin group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose rifampicin, isoniazid, and pyrazinamide
Rifampicin: 30mg/kg
Isoniazid: 300mg/day
Pyrazinamide: 1000mg/day (&lt;50kg), 1500mg/day (50-70kg), 2000mg /day (&gt;70kg), till culture conversion Duration of the treatment
Till 12 weeks after culture conversion on liquid media</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose rifampicin</intervention_name>
    <description>30mg/kg</description>
    <arm_group_label>Arm 2 (High-dose rifampicin group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>300mg</description>
    <arm_group_label>Arm 1 (Conventional treatment group)</arm_group_label>
    <arm_group_label>Arm 2 (High-dose rifampicin group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>20-30mg/kg</description>
    <arm_group_label>Arm 1 (Conventional treatment group)</arm_group_label>
    <arm_group_label>Arm 2 (High-dose rifampicin group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>15-20mg/kg</description>
    <arm_group_label>Arm 1 (Conventional treatment group)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>10mg/kg</description>
    <arm_group_label>Arm 1 (Conventional treatment group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented positivity by sputum Xpert MTB/RIF assay

          -  Administration of current tuberculosis therapy (if any) for no more than 7 days (â‰¤7)
             at the time of enrolment.

        Exclusion Criteria:

          -  Negative on Xpert MTB/RIF assay

          -  Resistance to rifampicin as detected by an Xpert MTB/RIF assay

          -  Known resistance to isoniazid, rifampicin, or pyrazinamide

          -  HIV positive

          -  Cancer patient on anti-cancer chemotherapy

          -  Uncontrolled DM

          -  Chronic hepatitis, liver cirrhosis

          -  Any contraindications of drugs to be used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Rifampicin</keyword>
  <keyword>Treatment</keyword>
  <keyword>Shortening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

